MA54147A - Procédé de modification du profil de glycosylation d'une glycoprotéine recombinante produite dans une culture cellulaire - Google Patents

Procédé de modification du profil de glycosylation d'une glycoprotéine recombinante produite dans une culture cellulaire

Info

Publication number
MA54147A
MA54147A MA054147A MA54147A MA54147A MA 54147 A MA54147 A MA 54147A MA 054147 A MA054147 A MA 054147A MA 54147 A MA54147 A MA 54147A MA 54147 A MA54147 A MA 54147A
Authority
MA
Morocco
Prior art keywords
modifying
cell culture
recombinant glycoprotein
glycosylation profile
glycoprotein produced
Prior art date
Application number
MA054147A
Other languages
English (en)
Inventor
Tibor Balogh
Balázs Horváth
Gáspár Nagy
Ákos Putics
László Párta
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MA54147A publication Critical patent/MA54147A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA054147A 2018-11-07 2019-11-06 Procédé de modification du profil de glycosylation d'une glycoprotéine recombinante produite dans une culture cellulaire MA54147A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUP1800376A HU231514B1 (hu) 2018-11-07 2018-11-07 Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer

Publications (1)

Publication Number Publication Date
MA54147A true MA54147A (fr) 2022-02-16

Family

ID=89992786

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054147A MA54147A (fr) 2018-11-07 2019-11-06 Procédé de modification du profil de glycosylation d'une glycoprotéine recombinante produite dans une culture cellulaire

Country Status (11)

Country Link
US (1) US20220098634A1 (fr)
EP (1) EP3877539A1 (fr)
JP (2) JP2022512928A (fr)
KR (1) KR20210089220A (fr)
CN (1) CN113272440A (fr)
AU (1) AU2019376476A1 (fr)
BR (1) BR112021008458A2 (fr)
CA (1) CA3118604A1 (fr)
HU (1) HU231514B1 (fr)
MA (1) MA54147A (fr)
WO (1) WO2020094694A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230145083A (ko) * 2021-02-12 2023-10-17 론자 벤드 인코포레이티드 항체 생성물의 비푸코실화를 조절하는 방법
CA3222409A1 (fr) 2021-06-07 2022-12-15 Amgen Inc. Utilisation de fucosidase pour controler le taux d'afucosylation de proteines glycosylees
WO2024094457A1 (fr) * 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Procédé de production de compositions de glycoprotéines

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0435911B1 (fr) 1988-09-23 1996-03-13 Cetus Oncology Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2106299C (fr) 1991-03-18 2001-02-06 Junming Le Anticorps monoclonaux et chimeriques specifiques du facteur de necrose tumorale humain
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
WO1994011026A2 (fr) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
PL188192B1 (pl) 1996-02-09 2004-12-31 Abbott Lab Bermuda Ltd Izolowane ludzkie przeciwciało albo jego część wiążąca antygen, rekombinowane ludzkie przeciwciało albo jego część wiążąca antygen, kompozycje farmaceutyczne, izolowane kwasy nukleinowe, rekombinowany wektor ekspresyjny, komórka gospodarza, sposób syntetyzowania przeciwciała ludzkiego, które wiąże ludzki TNFalfa, sposób hamowania aktywności ludzkiego TNFalfa in vitro, przeciwciało albo jego częśćwiążąca antygen, zastosowanie przeciwciała albo jego części wiążącej antygen
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
ES2907826T3 (es) 2001-06-26 2022-04-26 Amgen Inc Anticuerpos para OPGL
PL2495307T3 (pl) * 2006-07-13 2018-07-31 Wyeth Llc Wytwarzanie czynnika krzepliwości krwi IX o polepszonym wzorze glikozylacji
WO2010138502A2 (fr) * 2009-05-26 2010-12-02 Momenta Pharmaceuticals, Inc. Production de glycoprotéines
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
EP2970875B1 (fr) * 2013-03-15 2020-04-15 F.Hoffmann-La Roche Ag Compositions de culture de cellules comprenant des antioxydants et procédés de production de polypeptides
EP4282975A3 (fr) 2013-07-23 2024-02-28 Biocon Limited Procédés pour contrôler les niveaux de fucosylation dans des protéines
MX2016009848A (es) * 2014-01-29 2017-02-17 Lg Life Sciences Ltd Método de modulación de la galactosilación de proteína recombinante mediante optimización de medio de cultivo.
SI3110961T1 (sl) 2014-02-27 2020-03-31 F. Hoffmann-La Roche Ag Modulacija rasti celic in glikozilacije pri rekombinantni proizvodnji glikoproteina
PL3227454T3 (pl) * 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
WO2016196621A1 (fr) * 2015-06-01 2016-12-08 Biogen Ma Inc. Supplémentation en manganèse pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
WO2017021871A1 (fr) 2015-08-03 2017-02-09 Dr. Reddy's Laboratories Limited Procédé de culture cellulaire pour la modulation de glycanes
HU231463B1 (hu) * 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
ES2875274T3 (es) * 2015-11-02 2021-11-10 Hoffmann La Roche Procedimientos de preparación de formas fucosiladas y afucosiladas de una proteína
JP2019500878A (ja) 2016-01-06 2019-01-17 オンコバイオロジクス，インコーポレイティド モノクローナル抗体組成物中の高分子量種、酸性荷電種、及び断片の低減
WO2017120347A1 (fr) 2016-01-06 2017-07-13 Oncobiologics, Inc. Modulation d'espèces afucosylées dans une composition d'anticorps monoclonal
WO2017134667A1 (fr) 2016-02-02 2017-08-10 Insight Biopharmaceuticals Ltd. Procédés de génération d'anticorps

Also Published As

Publication number Publication date
CN113272440A (zh) 2021-08-17
WO2020094694A1 (fr) 2020-05-14
KR20210089220A (ko) 2021-07-15
CA3118604A1 (fr) 2020-05-14
JP2022512928A (ja) 2022-02-07
HUP1800376A2 (hu) 2020-05-28
EP3877539A1 (fr) 2021-09-15
JP2024112833A (ja) 2024-08-21
HU231514B1 (hu) 2024-07-28
AU2019376476A1 (en) 2021-05-27
US20220098634A1 (en) 2022-03-31
BR112021008458A2 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
MA54147A (fr) Procédé de modification du profil de glycosylation d'une glycoprotéine recombinante produite dans une culture cellulaire
SG11202000679XA (en) Recombinant antibody having unique glycan profile produced by cho host cell with edited genome and preparation method thereof
WO2015084558A3 (fr) Système de moulage pour margelles de piscine
EP2845967A2 (fr) Feuille de fibre de verre creuse
IL279901A (en) Antibodies containing a polypeptide inserted in the frame 3 region
CN106351450A (zh) 一种建筑施工中悬挂式浇筑找平装置及浇筑方法
CN104153495A (zh) 一种多功能轻质混凝土幕墙的连接结构
EP3976799A4 (fr) Lignée cellulaire de multiplication auxotrophe pour la production de protéines recombinées et procédés associés
PH12017550085B1 (en) Column-pile connecting method and connecting structure
KR20120008580U (ko) 헤라
MA52007A (fr) Procédés d'amélioration de la viabilité cellulaire dans un bioréacteur de production
CN206289972U (zh) 波纹管卡接件以及钢筋架
EP3842667C0 (fr) Engin de construction autonome et procédé de commande d'un engin de construction autonome
MA41685A (fr) Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
CN104499613A (zh) 陶瓷薄板转角连接构件
RU146475U1 (ru) Уплотнитель анкера
CN205329552U (zh) 一种清水混凝土箱梁模板
CN203834808U (zh) 一种砌块墙体上的窗台梁
CN106245775B (zh) 一种可移动式建筑样板墙托盘
CN204402062U (zh) 一种混凝土柱体阳角防护工具
MA43246A (fr) Molécule d'acide nucléique, protéine de fusion et procédé pour modifier le matériel génétique d'une cellule
CN205741870U (zh) T形梁纵向接口
EP4039884C0 (fr) Culée de pont pourvue de parties préfabriquées en béton, ainsi que son procédé de fabrication
JP6250330B2 (ja) 壁構造
MX2018007957A (es) Sistema de panel de concreto y metodo para la formacion de componente de construccion de concreto reforzado.